Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (6)
  • Open Access


    Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells

    Yaqiong Tian*1, Zengli Zhang†1, Liyun Miao*, Zhimin Yang, Jie Yang*, Yinhua Wang§, Danwen Qian, Hourong Cai*, Yongsheng Wang*

    Oncology Research, Vol.24, No.5, pp. 295-303, 2016, DOI:10.3727/096504016X14648701447814

    Abstract Recently, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized nonsmall cell lung cancer (NSCLC) treatment. However, resistance remains a major obstacle. Anexelekto (AXL) is a member of receptor tyrosine kinases (RTKs) and shares the same downstream signaling pathways with EGFR, such as PI3K/AKT and MAPK/ERK. AXL overexpression in resistant tumors has been implicated in many previous studies in vitro and in vivo. In this study, we further examined whether expression of AXL and its downstream targets increased in gefitinib-resistant PC9 cells (PC9GR). In addition, we hypothesize that knocking down AXL in PC9GR and… More >

  • Open Access


    A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer

    Atsushi Fujiwara*, Masamichi Yoshida*, Hajime Fujimoto, Hiroki Nakahara, Kentaro Ito, Kota Nishihama§, Taro Yasuma§, Osamu Hataji, Osamu Taguchi, Corina N. D’Alessandro-Gabazza§, Esteban C. Gabazza§, Tetsu Kobayashi

    Oncology Research, Vol.26, No.7, pp. 1031-1036, 2018, DOI:10.3727/096504018X15151523767752

    Abstract Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy of NSCLC in Japan. Osimertinib can be indicated only against T790M+ lung cancer as a second-line therapy. However, whether gefitinib, erlotinib, or afatinib is most appropriate as a first-line therapy is still a controversial issue. The aim of this study was to compare the effectiveness of gefitinib, erlotinib, and afatinib. We retrospectively reviewed… More >

  • Open Access


    miR-202 Inhibits Cell Proliferation, Migration, and Invasion by Targeting Epidermal Growth Factor Receptor in Human Bladder Cancer

    Liqing Zhang*, Jianjiang Xu, Gaodi Yang*, Heng Li, Xiuxia Guo§

    Oncology Research, Vol.26, No.6, pp. 949-957, 2018, DOI:doi.org/10.3727/096504018X15149787144385

    Abstract Recent studies have demonstrated that miR-202 is associated with several types of cancer; however, the expression and function of miR-202 have not been investigated in bladder cancer. We analyzed the expression of miR-202 in bladder cancer tissues and adjacent noncancerous tissues. The effect of miR-202 on the proliferation, migration, and invasion was evaluated by in vitro assays. The target gene of miR-202 was assessed by luciferase reporter assay. In this study, miR-202 was found to be significantly downregulated in bladder cancer cell lines and tissues and was highly correlated with the T classification, N classification, More >

  • Open Access


    2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells

    Arya Sobhakumari*1, Kevin P. Orcutt†‡1, Laurie Love-Homan§, Christopher E. Kowalski†‡, Arlene D. Parsons, C. Michael Knudson†‡§¶, Andrean L. Simons*†‡§¶

    Oncology Research, Vol.24, No.1, pp. 55-64, 2016, DOI:10.3727/096504016X14586627440192

    Abstract Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve HNSCC patient treatment and overall survival. HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms. We have previously shown that inhibition of glycolysis with 2-deoxy-d-glucose (2DG) significantly enhanced the antitumor effects of cisplatin and radiation, which are commonly used to treat… More >

  • Open Access


    Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy

    Ching-Wen Huang*, Cheng-Jen Ma*†, Wei-Chih Su*, Yi-Ting Chen‡§, Hsiang-Lin Tsai, Yung-Sung Yeh*#, Tsung-Kun Chang*, Wen-Hung Hsu**††, Fang-Jung Yu**††, Jaw-Yuan Wang*¶‡‡§§¶¶##

    Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822

    Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study… More >

  • Open Access


    Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

    Yudie Yang*1, Xia Zhang†1, Yajie Gao*, Yan Dong*, Di Wang*, Yanping Huang*, Tianhao Qu*, Buqun Fan*, Qizheng Li*, Chunxia Zhang*, Xiaonan Cui*, Bin Zhang*

    Oncology Research, Vol.29, No.1, pp. 63-74, 2021, DOI:10.3727/096504022X16462176651719

    Abstract Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is More >

Displaying 1-10 on page 1 of 6. Per Page